Novo Nordisk targets Indian drugmaker Dr Reddy's over formulation, trademark claims
The semaglutide legal battle in India has entered a new phase, with Novo Nordisk taking on Dr. Reddy’s Laboratories over formulation patents and trademark concerns, just after the expiry of the patent...To view the full article, register now.
Already a subscriber? Click here to view full article